PRFX PainReform Ltd. Stock Quote

PRFX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | Israel

Index	-	P/E	-	EPS (ttm)	-	Insider Own	63.79%	Shs Outstand	8.91M	Perf Week	8.25%
Market Cap	56.13M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.21M	Perf Month	28.31%
Income	-	PEG	-	EPS next Q	-	Inst Own	12.22%	Short Float	13.30%	Perf Quarter	37.25%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.10	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	3.82 - 7.85	Perf YTD	40.94%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-19.75%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	64.92%	ATR	0.73
Employees	-	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	60.99	Volatility	15.84% 14.45%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.69	Prev Close	6.50
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	290.28K	Price	6.30
Recom	-	SMA20	17.59%	SMA50	30.39%	SMA200	29.19%	Volume	201,965	Change	-3.08%

Jan-07-21 08:30AM	PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference GlobeNewswire
Jan-06-21 08:30AM	PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations GlobeNewswire -5.17%
Jan-04-21 08:30AM	PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110 ACCESSWIRE
Nov-23-20 08:30AM	PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer ACCESSWIRE +10.34%
Nov-12-20 09:00AM	PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors ACCESSWIRE
Nov-05-20 08:30AM	PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors ACCESSWIRE
Oct-19-20 09:00AM	PainReform Highlights Surgical Advantages of PRF-110 ACCESSWIRE
Sep-29-20 07:30AM	PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials ACCESSWIRE
Sep-09-20 02:15PM	PainReform Announces Closing of $20.0 Million Initial Public Offering ACCESSWIRE

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of products for the treatment of pain in Israel. It develops PRF-110, a product based on local anesthetic ropivacaine, which completed Phase II clinical study in hernia repair. The company was founded in 2007 and is headquartered in Herzeliya, Israel.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience